Introduction: Who Should Undergo Diagnostics
If you’re experiencing persistent fatigue, unusual weakness, or shortness of breath that doesn’t seem to improve with rest, it may be time to talk with your doctor. Myelodysplastic syndrome with excess blasts, often called MDS-EB, typically affects older adults, most commonly those over 60 years of age. However, people of any age can develop this condition, and recognizing the warning signs early can make a significant difference in managing the disease.[1][6]
You should consider seeking diagnostic testing if you notice unusual paleness in your skin, which happens when your body doesn’t have enough healthy red blood cells. Frequent infections that seem to occur more often than usual could indicate that your white blood cell count is too low. Similarly, if you bruise easily or experience bleeding that won’t stop easily, such as from the gums or nose, this might signal that your platelet levels have dropped. Some people also notice tiny red spots just beneath the skin, called petechiae, which appear when small blood vessels leak.[1][14]
It’s important to understand that many people with MDS-EB don’t experience obvious symptoms in the early stages. The condition often develops slowly, and symptoms may be subtle at first, gradually worsening over time. This is why healthcare providers sometimes discover the condition during routine blood tests performed for other reasons. If you have a history of chemotherapy or radiation treatment for cancer, you face a higher risk of developing MDS-EB years after your treatment ended. People who have been exposed to certain workplace chemicals may also be at increased risk.[3][15]
Classic Diagnostic Methods
Diagnosing myelodysplastic syndrome with excess blasts requires several different types of tests that work together to give doctors a complete picture of what’s happening in your bone marrow and blood. The diagnostic process begins with a thorough medical history and physical examination. Your doctor will ask about your symptoms, how long you’ve had them, any previous cancer treatments, and whether you’ve been exposed to chemicals or toxins that might increase your risk.[6]
Complete Blood Count
The first and most fundamental test is a complete blood count, commonly known as a CBC. This simple blood test measures the levels of different types of cells in your blood: red blood cells that carry oxygen, white blood cells that fight infection, and platelets that help your blood clot. In people with MDS-EB, the CBC typically shows lower than normal levels of at least one, and often two or more, of these blood cell types. Your doctor will look specifically at whether you have anemia (too few red blood cells), neutropenia (too few white blood cells), or thrombocytopenia (too few platelets).[6][11]
When the CBC results show abnormalities, your doctor will examine a sample of your blood under a microscope. This examination, called a blood smear, allows them to see the shape and appearance of your blood cells. In MDS-EB, the blood cells often look abnormal or immature. Your doctor will count how many blast cells are present in your blood. These are very early, immature blood cells that haven’t developed properly. In a healthy person, blast cells make up less than 5 percent of blood cells, but in MDS-EB, you’ll have more than normal.[7][10]
Bone Marrow Examination
To confirm a diagnosis of MDS-EB, doctors need to examine your bone marrow directly. This involves two procedures performed at the same time: a bone marrow aspiration and a bone marrow biopsy. These procedures are typically done in the hip bone area. During aspiration, your doctor uses a hollow needle to withdraw a small amount of the liquid portion of your bone marrow. For the biopsy, they remove a tiny piece of bone containing marrow inside it.[6]
The bone marrow samples provide crucial information. A specialist called a pathologist examines them under a microscope to count the percentage of blast cells present and to look for abnormal cell shapes and structures. In MDS-EB1, blast cells make up between 5 and 9 percent of the cells in the bone marrow, or between 2 and 4 percent of cells in the blood. In MDS-EB2, which carries a higher risk of progressing to acute myeloid leukemia, blast cells make up between 10 and 19 percent of cells in the bone marrow, or between 5 and 19 percent of cells in the blood.[6][11]
Genetic and Chromosomal Testing
Genetic testing of your bone marrow and blood samples provides additional important information. Cytogenetic testing examines the chromosomes inside your cells to look for abnormalities. Chromosomes are structures that contain your genes, and changes in chromosomes can affect how cells grow and function. Common chromosomal changes found in MDS-EB include deletions or losses of parts of chromosomes 5, 7, or 20, complete loss of chromosome 5 or 7, or an extra copy of chromosome 8. These findings help doctors understand how aggressive your disease might be and what treatment options may work best.[5][11]
More specialized DNA testing, called next-generation sequencing, can identify specific gene mutations within your cells. Examples of gene mutations commonly found in MDS cells include changes in genes called SF3B1 and TP53. These genetic details help doctors classify your specific type of MDS and predict how the disease might progress. Some genetic findings suggest a better outlook, while others indicate a higher risk of progression to acute leukemia.[5][15]
Additional Laboratory Tests
Your doctor may order additional blood tests to rule out other conditions that can cause similar symptoms. These might include tests to check your vitamin B12 and folate levels, as deficiencies in these nutrients can also cause abnormal blood cell production. Tests for iron levels are important because some forms of MDS involve unusual iron storage in red blood cells. Your doctor will also want to evaluate your kidney and liver function, as these organs play important roles in blood cell health.[17]
Diagnostics for Clinical Trial Qualification
If you’re considering participating in a clinical trial for MDS-EB, you’ll need to undergo additional testing beyond the standard diagnostic procedures. Clinical trials are research studies that test new treatments or combinations of treatments, and they have specific requirements, called eligibility criteria, that determine who can participate. Understanding these requirements can help you know what to expect if you’re interested in exploring clinical trial options.[2][12]
Risk Stratification Systems
Clinical trials often use standardized scoring systems to categorize patients based on their disease characteristics. The most widely used system is called the International Prognostic Scoring System, or IPSS, and its updated version, the Revised International Prognostic Scoring System, known as R-IPSS. These systems assign points based on the percentage of blast cells in your bone marrow, the types of chromosomal abnormalities present, and how many of your blood cell types have low counts.[3][15]
The IPSS-R categorizes patients into different risk groups: very low, low, intermediate, high, and very high risk. This classification helps determine which clinical trials might be appropriate for you. Some trials specifically enroll patients with lower-risk disease, while others focus on intermediate or high-risk patients. The risk category also helps researchers predict how quickly the disease might progress and helps ensure that different trials are comparing similar groups of patients.[2][12]
Baseline Testing Requirements
Before you can enroll in a clinical trial, researchers need comprehensive baseline information about your health status. This typically includes repeating many of the standard diagnostic tests, even if you’ve had them done recently. Clinical trials require fresh test results, often performed within a specific timeframe before you start the experimental treatment, to ensure accurate comparisons as the study progresses.
You’ll need updated complete blood counts and bone marrow examinations to confirm your blast cell percentage and disease classification. The trial may require that these tests be reviewed by a central laboratory to ensure consistency in how results are interpreted. Some trials also mandate specific genetic testing to identify whether you have particular chromosomal abnormalities or gene mutations that might affect how you respond to the treatment being studied.[2][12]
Performance Status and Health Assessments
Clinical trials need to assess your overall health and your ability to perform daily activities. This is measured using something called performance status, which rates how well you can care for yourself and carry out normal activities. Different scoring systems exist, but they all evaluate similar factors: whether you’re able to work, whether you can care for yourself, and how much time you spend in bed or resting during the day.
You may also need to undergo tests to evaluate the function of your major organs, particularly your heart, liver, and kidneys. Many experimental treatments can affect these organs, so researchers need to know that they’re functioning adequately before you start treatment. Blood tests that measure liver enzymes, kidney function markers, and sometimes heart function tests like electrocardiograms may be required. These assessments help ensure your safety during the trial and help researchers understand whether any problems that develop during treatment are related to the experimental therapy or to pre-existing conditions.[13]
Transfusion History Documentation
Some clinical trials, particularly those testing treatments for anemia in MDS, require detailed documentation of your transfusion history. Researchers may need to know how many red blood cell transfusions you’ve received in recent months and whether you’re considered “transfusion dependent,” meaning you need regular transfusions to maintain adequate blood counts. This information helps determine whether you meet the trial’s eligibility requirements and provides a baseline for measuring whether the experimental treatment reduces your need for transfusions.[2][12]